company background image
BGBIO logo

BerGenBio OB:BGBIO Stock Report

Last Price

kr0.19

Market Cap

kr521.6m

7D

-1.0%

1Y

-96.1%

Updated

28 Mar, 2024

Data

Company Financials +

BGBIO Stock Overview

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases.

BGBIO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

BerGenBio ASA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BerGenBio
Historical stock prices
Current Share Pricekr0.19
52 Week Highkr4.95
52 Week Lowkr0.075
Beta1.39
1 Month Change1.04%
3 Month Change-30.22%
1 Year Change-96.06%
3 Year Change-99.37%
5 Year Change-99.20%
Change since IPO-99.22%

Recent News & Updates

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

Dec 07
Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

Recent updates

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

Dec 07
Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Aug 24
BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Feb 06
BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Sep 26
Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Jun 11
Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Feb 17
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

Sep 21
We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

Mar 13
It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

Feb 11
We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

Dec 21
What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

Shareholder Returns

BGBIONO BiotechsNO Market
7D-1.0%2.6%1.2%
1Y-96.1%-68.7%4.1%

Return vs Industry: BGBIO underperformed the Norwegian Biotechs industry which returned -68.7% over the past year.

Return vs Market: BGBIO underperformed the Norwegian Market which returned 5.4% over the past year.

Price Volatility

Is BGBIO's price volatile compared to industry and market?
BGBIO volatility
BGBIO Average Weekly Movement13.1%
Biotechs Industry Average Movement9.3%
Market Average Movement5.3%
10% most volatile stocks in NO Market10.3%
10% least volatile stocks in NO Market2.8%

Stable Share Price: BGBIO's share price has been volatile over the past 3 months.

Volatility Over Time: BGBIO's weekly volatility has decreased from 27% to 13% over the past year, but is still higher than 75% of Norwegian stocks.

About the Company

FoundedEmployeesCEOWebsite
200725Martin Olinhttps://www.bergenbio.com

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma.

BerGenBio ASA Fundamentals Summary

How do BerGenBio's earnings and revenue compare to its market cap?
BGBIO fundamental statistics
Market capkr521.61m
Earnings (TTM)-kr190.40m
Revenue (TTM)kr354.00k

1,473x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BGBIO income statement (TTM)
Revenuekr354.00k
Cost of Revenuekr0
Gross Profitkr354.00k
Other Expenseskr190.76m
Earnings-kr190.40m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 30, 2024

Earnings per share (EPS)-0.071
Gross Margin100.00%
Net Profit Margin-53,785.59%
Debt/Equity Ratio0%

How did BGBIO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.